These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 27670739)
1. High throughput cell-based assay for identification of glycolate oxidase inhibitors as a potential treatment for Primary Hyperoxaluria Type 1. Wang M; Xu M; Long Y; Fargue S; Southall N; Hu X; McKew JC; Danpure CJ; Zheng W Sci Rep; 2016 Sep; 6():34060. PubMed ID: 27670739 [TBL] [Abstract][Full Text] [Related]
2. Effects of alanine:glyoxylate aminotransferase variants and pyridoxine sensitivity on oxalate metabolism in a cell-based cytotoxicity assay. Fargue S; Knight J; Holmes RP; Rumsby G; Danpure CJ Biochim Biophys Acta; 2016 Jun; 1862(6):1055-62. PubMed ID: 26854734 [TBL] [Abstract][Full Text] [Related]
3. Reconstruction of human hepatocyte glyoxylate metabolic pathways in stably transformed Chinese-hamster ovary cells. Behnam JT; Williams EL; Brink S; Rumsby G; Danpure CJ Biochem J; 2006 Mar; 394(Pt 2):409-16. PubMed ID: 16309382 [TBL] [Abstract][Full Text] [Related]
4. Multiple mechanisms of action of pyridoxine in primary hyperoxaluria type 1. Fargue S; Rumsby G; Danpure CJ Biochim Biophys Acta; 2013 Oct; 1832(10):1776-83. PubMed ID: 23597595 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of Glycolate Oxidase With Dicer-substrate siRNA Reduces Calcium Oxalate Deposition in a Mouse Model of Primary Hyperoxaluria Type 1. Dutta C; Avitahl-Curtis N; Pursell N; Larsson Cohen M; Holmes B; Diwanji R; Zhou W; Apponi L; Koser M; Ying B; Chen D; Shui X; Saxena U; Cyr WA; Shah A; Nazef N; Wang W; Abrams M; Dudek H; Salido E; Brown BD; Lai C Mol Ther; 2016 Apr; 24(4):770-8. PubMed ID: 26758691 [TBL] [Abstract][Full Text] [Related]
6. Glycolate oxidase deficiency in a patient with congenital hyperinsulinism and unexplained hyperoxaluria. Clifford-Mobley O; Rumsby G; Kanodia S; Didi M; Holt R; Senniappan S Pediatr Nephrol; 2017 Nov; 32(11):2159-2163. PubMed ID: 28752386 [TBL] [Abstract][Full Text] [Related]
7. Glycolate Oxidase Is a Safe and Efficient Target for Substrate Reduction Therapy in a Mouse Model of Primary Hyperoxaluria Type I. Martin-Higueras C; Luis-Lima S; Salido E Mol Ther; 2016 Apr; 24(4):719-25. PubMed ID: 26689264 [TBL] [Abstract][Full Text] [Related]
8. Immunocytochemical localization of human hepatic alanine: glyoxylate aminotransferase in control subjects and patients with primary hyperoxaluria type 1. Cooper PJ; Danpure CJ; Wise PJ; Guttridge KM J Histochem Cytochem; 1988 Oct; 36(10):1285-94. PubMed ID: 3418107 [TBL] [Abstract][Full Text] [Related]
9. Oxalate synthesis in mammals: properties and subcellular distribution of serine:pyruvate/alanine:glyoxylate aminotransferase in the liver. Ichiyama A; Xue HH; Oda T; Uchida C; Sugiyama T; Maeda-Nakai E; Sato K; Nagai E; Watanabe S; Takayama T Mol Urol; 2000; 4(4):333-40. PubMed ID: 11156700 [TBL] [Abstract][Full Text] [Related]
10. Primary hyperoxaluria type 1: novel therapies at a glance. Bacchetta J; Lieske JC Clin Kidney J; 2022 May; 15(Suppl 1):i17-i22. PubMed ID: 35592618 [TBL] [Abstract][Full Text] [Related]
11. Primary hyperoxaluria type 1: pathophysiology and genetics. Fargue S; Acquaviva Bourdain C Clin Kidney J; 2022 May; 15(Suppl 1):i4-i8. PubMed ID: 35592619 [TBL] [Abstract][Full Text] [Related]
12. Primary hyperoxaluria type 1 in Japan. Ichiyama A; Oda T; Maeda-Nakai E Cell Biochem Biophys; 2000; 32 Spring():171-6. PubMed ID: 11330044 [TBL] [Abstract][Full Text] [Related]
13. [From gene to disease; primary hyperoxaluria type I caused by mutations in the AGXT gene]. van Woerden CS; Groothof JW; Wanders RJ; Waterham HR; Wijburg FR Ned Tijdschr Geneeskd; 2006 Jul; 150(30):1669-72. PubMed ID: 16922352 [TBL] [Abstract][Full Text] [Related]
14. Active site and loop 4 movements within human glycolate oxidase: implications for substrate specificity and drug design. Murray MS; Holmes RP; Lowther WT Biochemistry; 2008 Feb; 47(8):2439-49. PubMed ID: 18215067 [TBL] [Abstract][Full Text] [Related]
15. Potential mechanisms of marked hyperoxaluria not due to primary hyperoxaluria I or II. Monico CG; Persson M; Ford GC; Rumsby G; Milliner DS Kidney Int; 2002 Aug; 62(2):392-400. PubMed ID: 12110000 [TBL] [Abstract][Full Text] [Related]
16. Primary hyperoxaluria type 1: AGT mistargeting highlights the fundamental differences between the peroxisomal and mitochondrial protein import pathways. Danpure CJ Biochim Biophys Acta; 2006 Dec; 1763(12):1776-84. PubMed ID: 17027096 [TBL] [Abstract][Full Text] [Related]
17. High incidence of hyperoxaluria in generalized peroxisomal disorders. van Woerden CS; Groothoff JW; Wijburg FA; Duran M; Wanders RJ; Barth PG; Poll-The BT Mol Genet Metab; 2006 Aug; 88(4):346-50. PubMed ID: 16621644 [TBL] [Abstract][Full Text] [Related]
18. Advances in the enzymology and molecular genetics of primary hyperoxaluria type 1. Prospects for gene therapy. Danpure CJ Nephrol Dial Transplant; 1995; 10 Suppl 8():24-9. PubMed ID: 8592621 [TBL] [Abstract][Full Text] [Related]
19. Novel Starting Points for Human Glycolate Oxidase Inhibitors, Revealed by Crystallography-Based Fragment Screening. Mackinnon SR; Bezerra GA; Krojer T; Szommer T; von Delft F; Brennan PE; Yue WW Front Chem; 2022; 10():844598. PubMed ID: 35601556 [TBL] [Abstract][Full Text] [Related]
20. Pyridoxamine and pyridoxal are more effective than pyridoxine in rescuing folding-defective variants of human alanine:glyoxylate aminotransferase causing primary hyperoxaluria type I. Oppici E; Fargue S; Reid ES; Mills PB; Clayton PT; Danpure CJ; Cellini B Hum Mol Genet; 2015 Oct; 24(19):5500-11. PubMed ID: 26199318 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]